SERINA MADDEN ARNP-FNP-C
Prescription History 1548711021
Nurse Practitioner in Oklahoma City, OK

NPI Status: Active since October 19, 2016

Contact Information

711 STANTON L YOUNG BLVD STE 430
OKLAHOMA CITY, OK
ZIP 73104
Phone: (405) 271-6434
Fax: (405) 271-6264

Get Directions

Prescription History for Informed Healthcare Decisions

Explore the verified Medicare Part D prescription history, volume metrics, and calculated drug costs for SERINA MADDEN ARNP-FNP-C, an active Nurse Practitioner specialist practicing in Oklahoma City, OK. Our medical registry currently tracks 4 unique pharmaceutical formulations prescribed by this provider, representing an estimated volume of 133 documented patient claims. Among these therapy options, the most frequently utilized medication is Descovy, which accounts for 95 claims alone.

Medication Index

No matching medications currently found on file.

Descovy

Generic Formulation: Emtricitabine/Tenofov AlafenamSpecialty: Nurse Practitioner
Provider Metrics Summary
Total Claims 95
30-Day Fills 99.0
Days Supply 2,970
OK State Average Benchmarks
Peer Average Claims45.0
Peer Average 30-Day Fills46.3
Peer Average Days Supply1,354
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 111.1% higher than the standard regional baseline profile for OK. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $227,402.11 across this reporting matrix range.

Provider Avg Cost Per Claim

$2,393.71

State Avg Cost Per Claim

$2,170.04

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This product is used with other HIV medications to help control HIV infection. It helps to decrease the amount of HIV in your body so your immune system can work better. This lowers your chance of getting HIV complications (such as new infections, cancer) and improves your quality of life. This product is a combination of two different drugs: emtricitabine and tenofovir alafenamide. Emtricitabine is called a nucleoside reverse transcriptase inhibitor, while tenofovir alafenamide is called a nucleotide reverse transcriptase inhibitor. They are often called NRTIs. This product should not be used by itself to help control HIV infection. Doing so can make your treatment less effective. Use combination treatment with at least one other HIV medication. This product is also approved in the US to help prevent HIV infection in people who have a high risk for infection. Some things that increase risk include having a partner infected with HIV, having unprotected sex, having multiple sex partners, infection with a sexually transmitted disease-STD, or use/abuse of drugs or alcohol. Emtricitabine/tenofovir alafenamide is not a cure for HIV infection. To decrease your risk of spreading HIV disease to others, continue to take all HIV medications exactly as prescribed by your doctor. Use an effective barrier method (latex or polyurethane condoms/dental dams) during sexual activity as directed by your doctor. Do not share personal items (such as needles/syringes, toothbrushes, and razors) that may have contacted blood or other body fluids. Consult your doctor or pharmacist for more details.

Emtricitabine-Tenofovir Disop

Generic Formulation: Emtricitabine/Tenofovir (Tdf)Specialty: Nurse Practitioner
Provider Metrics Summary
Total Claims 13
30-Day Fills 17.0
Days Supply 510
OK State Average Benchmarks
Peer Average Claims19.0
Peer Average 30-Day Fills19.6
Peer Average Days Supply562
Conservative Utilization

This provider writes prescriptions for this formulation 31.6% less frequently than the standard regional baseline metric for practitioners inside OK. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $1,692.94 across this reporting matrix range.

Provider Avg Cost Per Claim

$130.23

State Avg Cost Per Claim

$252.78

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A pharmaceutical preparation of emtricitabine and tenofovir that is used as an ANTI-HIV AGENT in the treatment and prevention of HIV INFECTIONS.

Therapeutic Applications

This product is used with other HIV medications to help control HIV infection. It helps to decrease the amount of HIV in your body so your immune system can work better. This lowers your chance of getting HIV complications (such as new infections, cancer) and improves your quality of life. This product is a combination of two different drugs: emtricitabine and tenofovir. Emtricitabine is called a nucleoside reverse transcriptase inhibitor, while tenofovir is called a nucleotide reverse transcriptase inhibitor. They are often called NRTIs. This product should not be used by itself to help control HIV infection. Doing so can make your treatment less effective. Combination treatment with at least one other HIV medication should be used. This product is also used to help prevent HIV infection in people who have a high risk for infection. Some things that increase risk include having a partner infected with HIV, having unprotected sex, having multiple sex partners, infection with a sexually transmitted disease-STD, or use/abuse of drugs or alcohol. Emtricitabine/tenofovir is not a cure for HIV infection. To decrease your risk of spreading HIV disease to others, continue to take all HIV medications exactly as prescribed by your doctor. Use an effective barrier method (latex or polyurethane condoms/dental dams) during sexual activity as directed by your doctor. Do not share personal items (such as needles/syringes, toothbrushes, and razors) that may have contacted blood or other body fluids. Consult your doctor or pharmacist for more details.

Estradiol

Generic Formulation: EstradiolSpecialty: Nurse Practitioner
Provider Metrics Summary
Total Claims 11
30-Day Fills 11.0
Days Supply 330
OK State Average Benchmarks
Peer Average Claims34.0
Peer Average 30-Day Fills80.9
Peer Average Days Supply2,413
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 67.6% less volume than the regional standard for practitioners inside OK. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $233.48 across this reporting matrix range.

Provider Avg Cost Per Claim

$21.23

State Avg Cost Per Claim

$46.53

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

The 17-beta-isomer of estradiol, an aromatized C18 steroid with hydroxyl group at 3-beta- and 17-beta-position. Estradiol-17-beta is the most potent form of mammalian estrogenic steroids.

Therapeutic Applications

This medication is a female hormone (estrogen). It is used by women to help reduce symptoms of menopause (such as hot flashes, vaginal dryness). These symptoms are caused by the body making less estrogen. If you are using this medication to treat symptoms only in and around the vagina, products applied directly inside the vagina should be considered before medications that are taken by mouth, absorbed through the skin, or injected. This medication may also be used by women who are not able to produce enough estrogen (for example, due to hypogonadism, primary ovarian failure). Certain estrogen products may also be used by women after menopause to prevent bone loss (osteoporosis). However, there are other medications (such as raloxifene, bisphosphonates including alendronate) that are also effective in preventing bone loss and may be safer. These medications should be considered for use before estrogen treatment.

Testosterone Cypionate

Generic Formulation: Testosterone CypionateSpecialty: Nurse Practitioner
Provider Metrics Summary
Total Claims 14
30-Day Fills 15.1
Days Supply 316
OK State Average Benchmarks
Peer Average Claims23.0
Peer Average 30-Day Fills43.5
Peer Average Days Supply1,263
Conservative Utilization

This provider writes prescriptions for this formulation 39.1% less frequently than the standard regional baseline metric for practitioners inside OK. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $158.73 across this reporting matrix range.

Provider Avg Cost Per Claim

$11.34

State Avg Cost Per Claim

$47.54

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This medication is used in men who do not make enough of a natural substance called testosterone. In males, testosterone is responsible for many normal functions, including growth and development of the genitals, muscles, and bones. It also helps cause normal sexual development (puberty) in boys. Testosterone belongs to a class of drugs known as androgens. It works by affecting many body systems so that the body can develop and function normally. Testosterone may also be used in certain adolescent boys to cause puberty in those with delayed puberty. It may also be used to treat certain types of breast cancer in women.

Dataset Methodology & CMS Source Information

This analytical profile maps public infrastructure records sourced directly from official **Centers for Medicare & Medicaid Services (CMS)** public data releases. The statistics above track documented pharmaceutical treatment trends assigned to beneficiaries specifically under federal public programs. Evaluating the prescriptive footprints of clinical practitioners like SERINA MADDEN ARNP-FNP-C provides transparency into local medical care patterns within Oklahoma City, OK.

Key Learning Objectives for this Profile:

  • Prescribing Frequencies: Track and evaluate the volume metrics of specific brand-name and generic medical formulas chosen by this provider over time.
  • Clinical Focus Areas: Identify how the provider distributes therapeutic selections across medical care options to gain insight into their true day-to-day **Nurse Practitioner** practice concentrations.
  • Program Cost Awareness: Review the calculated total systemic drug costs and raw transactional volumes linked to these orders to better anticipate network insurance coverage structures.
  • Patient-Centered Evaluation: Cross-reference localized regional care comparisons to align practitioner habits directly with your proactive health maintenance goals.

Data Scope Exclusion & Limitations: The data elements presented above explicitly reflect prescription orders processed for Medicare beneficiaries during the year 2023. This informational profile does not aggregate prescription data for individuals utilizing private commercial health plans, state Medicaid coverage, or self-pay options. However, because medical decision-making remains highly consistent across clinical settings, this public registry provides a reliable proxy for understanding the general prescribing preferences and pharmaceutical care approach used by this provider.